Gui-Feng Kang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3447114/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Discovery of small-molecule inhibitors of RUVBL1/2 ATPase. Bioorganic and Medicinal Chemistry, 2022, 62, 116726.	3.0	8
2	Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity. Journal of Medicinal Chemistry, 2021, 64, 7702-7723.	6.4	8
3	Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimer. RSC Medicinal Chemistry, 2020, 11, 125-131.	3.9	6
4	Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry. ACS Medicinal Chemistry Letters, 2020, 11, 2318-2324.	2.8	7
5	One-pot synthesis of 1,3,5-triazine-2,4-dithione derivatives via three-component reactions. Beilstein Journal of Organic Chemistry, 2020, 16, 1447-1455.	2.2	6
6	Novel nano-materials, RGD-tetrapeptide-modified 17β-amino-11α-hydroxyandrost-1,4-diene-3-one: synthesis, self-assembly based nano-images and in vivo anti-osteoporosis evaluation. Journal of Materials Chemistry, 2012, 22, 4652.	6.7	10
7	Development of three-component conjugates: to get nano-globes with porous surfaces, high in vivo anti-osteoporosis activity and minimal side effects. Journal of Materials Chemistry, 2012, 22, 21740.	6.7	8
8	N-[2(3-Carboxyl-9-benzyl-carboline-1-yl)ethyl-1-yl]-amino acids: correlation of spectral property with in vivo anti-tumor activity. Medicinal Chemistry Research, 2012, 21, 116-123.	2.4	4